K. Homicsko

Discipline

Psychologie (2) Economies et finances (2)

Type de document

Articles (21) Recensions (3)

Co-auteur

Date

Source

Mot-clé

Treatment (15) thérapie (12) Therapeutics (12) Patients (11) Human beings (11) Patients (11) cancer (9) Cancer (9) Cancer (9) Use (9) Inhibitors (8) Melanoma (8) norme (6) maladie (6) survie (6) Case (6) Survival (6) Inhibition (6) Grammar, Comparative and general--Case (6) Case (6) maladie (6) analyse (5) Analysis (5) temps (durée) (4) oncologie (4) mutation (4) gène (4) dosage (4) Chemotherapy (4) Time (4)

Documents écrit par K. Homicsko (21) | parle de K. Homicsko (0)

Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient.
S. Anchisi et al. (31 déc. 2023)
Response and Resistance to Trametinib in MAP2K1-Mutant Triple-Negative Melanoma.
F.S. Krebs et al. (24 févr. 2023)
Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages.
M. Tichet et al. (10 janv. 2023)
Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma.
B. Gautron Moura et al. (21 déc. 2022)
First communication on the efficacy of combined 177Lutetium-PSMA with immunotherapy outside prostate cancer.
A. Digklia et al.
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
K. Homicsko et al. (5 mai 2022)
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal Melanoma.
V. Aedo-Lopez et al. (24 févr. 2022)
Ovarian cancer with high-level focal ERBB2 amplification responds to trastuzumab and pertuzumab.
L. Thouvenin et al.
Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology.
F.S. Krebs et al. (28 oct. 2020)
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
A. Huber et al. (27 mai 2020)
Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss.
D. Frisone et al. (2020)
Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.
M. Viala et al. (6 mars 2018)
Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".
S. Voruz et al.
Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.
S. Voruz et al.
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).
W. Wick et al. (1 oct. 2016)
Compact solid-state CMOS single-photon detector array for in vivo NIR fluorescence lifetime oncology measurements.
H.A. Homulle et al. (2016)
The consensus molecular subtypes of colorectal cancer.
J. Guinney et al. (2015)
Standards of care and novel approaches in the management of glioblastoma multiforme.
A.F. Hottinger et al. (2014)
A colorectal cancer classification system that associates cellular phenotype and responses to therapy.
A. Sadanandam et al. (2013)
Decision making and management of gliomas: practical considerations.
A.F. Hottinger et al. (2012)
Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
C. Fuerer et al. (4 oct. 2006)